Lexeo Therapeutics Inc [NASDAQ: LXEO] price surged by 22.24 percent to reach at $1.19.
A sum of 4940950 shares traded at recent session while its average daily volume was at 446.52K shares. Lexeo Therapeutics Inc shares reached a high of $7.4 and dropped to a low of $5.275 until finishing in the latest session at $6.54.
The one-year LXEO stock forecast points to a potential upside of 60.07. The average equity rating for LXEO stock is currently 1.12, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Lexeo Therapeutics Inc [LXEO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXEO shares is $16.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXEO stock is a recommendation set at 1.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Lexeo Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 31, 2025. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on June 13, 2024, representing the official price target for Lexeo Therapeutics Inc stock. Previously, the target price had yet another raise to $22, while H.C. Wainwright analysts kept a Buy rating on LXEO stock.
The Price to Book ratio for the last quarter was 2.56, with the Price to Cash per share for the same quarter was set at 2.46.
LXEO Stock Performance Analysis:
Lexeo Therapeutics Inc [LXEO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.01. With this latest performance, LXEO shares gained by 40.34% in over the last four-week period, additionally plugging by 47.30% over the last 6 months – not to mention a drop of -0.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXEO stock in for the last two-week period is set at 77.42, with the RSI for the last a single of trading hit 0.53, and the three-weeks RSI is set at 0.42 for Lexeo Therapeutics Inc [LXEO]. The present Moving Average for the last 50 days of trading for this stock 4.77, while it was recorded at 5.56 for the last single week of trading, and 4.39 for the last 200 days.
Lexeo Therapeutics Inc (LXEO) Capital Structure & Debt Analysis
According to recent financial data for Lexeo Therapeutics Inc. ( LXEO), the Return on Equity (ROE) stands at -75.32%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -62.04%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Lexeo Therapeutics Inc’s Return on Invested Capital (ROIC) is -79.03%, showcasing its effectiveness in deploying capital for earnings.
Lexeo Therapeutics Inc (LXEO) Efficiency & Liquidity Metrics
Based on Lexeo Therapeutics Inc’s (LXEO) latest financial statements, the Debt-to-Equity Ratio is 0.06%, indicating its reliance on debt financing relative to shareholder equity.
Lexeo Therapeutics Inc (LXEO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Lexeo Therapeutics Inc. (LXEO) effectively leverages its workforce, generating an average of -$1585694.44 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.43% and a Quick Ratio of 4.43%, indicating strong ability to cover short-term liabilities.
LXEO Stock EPS
With the latest financial reports released by the company, Lexeo Therapeutics Inc posted -0.89/share EPS, while the average EPS was predicted by analysts to be reported at -0.67/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.22. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LXEO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lexeo Therapeutics Inc go to 21.36%.
Lexeo Therapeutics Inc [LXEO] Institutonal Ownership Details
There are presently around $89.38%, or 89.86%% of LXEO stock, in the hands of institutional investors. The top three institutional holders of LXEO stocks are: EVENTIDE ASSET MANAGEMENT, LLC with ownership of 3.37 million shares, which is approximately 10.2089%. JANUS HENDERSON GROUP PLC, holding 3.16 million shares of the stock with an approximate value of $$50.73 million in LXEO stocks shares; and JANUS HENDERSON GROUP PLC, currently with $$41.67 million in LXEO stock with ownership which is approximately 7.8715%.
